PMID- 27921224
OWN - NLM
STAT- MEDLINE
DCOM- 20171012
LR  - 20181202
IS  - 1433-7339 (Electronic)
IS  - 0941-4355 (Linking)
VI  - 25
IP  - 5
DP  - 2017 May
TI  - Hyperacute peripheral neuropathy is a predictor of oxaliplatin-induced persistent 
      peripheral neuropathy.
PG  - 1383-1389
LID - 10.1007/s00520-016-3514-6 [doi]
AB  - PURPOSE: Chronic peripheral neuropathy is a major adverse response to 
      oxaliplatin-containing chemotherapy regimens, but there are no established risk 
      factors pertaining to it. We investigated the efficacy of hyperacute peripheral 
      neuropathy (HAPN) as a predictor of oxaliplatin-induced persistent peripheral 
      neuropathy (PPN). METHODS: Forty-seven cases of stage III colorectal cancer who 
      received adjuvant chemotherapy with oxaliplatin after curative surgery between 
      January 2010 and August 2014 were retrospectively reviewed. HAPN was defined as 
      acute peripheral neuropathy (APN) occurring on day 1 (</=24 h after oxaliplatin 
      infusion) of the first cycle. PPN was defined as neuropathy lasting >1 year after 
      oxaliplatin discontinuation. RESULTS: The average total dose of oxaliplatin was 
      625.8 mg/m(2), and the average relative dose intensity was 66.7%. Twenty-two of 
      the 47 patients (46.8%) had PPN and 13 (27.7%) had HAPN. Male sex, treatment for 
      neuropathy, HAPN, and APN were significantly more frequent in patients with PPN 
      (p = 0.013, 0.02, <0.001, and 0.023, respectively). There was no significant 
      difference in the total oxaliplatin dose between patients with and without PPN 
      (p = 0.061). Multivariate analyses revealed total dose of oxaliplatin and HAPN as 
      independent predictors of PPN [p = 0.015; odds ratio (OR) = 1.005, 95% confidence 
      interval (CI), 1.001-1.009 and p = 0.001; OR = 75.307, 5.3-1070.123, 
      respectively]. The total dose of oxaliplatin was relatively lower in patients 
      with HAPN than that in those without HAPN in the PPN-positive group (not 
      significant, p = 0.068). CONCLUSION: HAPN was found to be a predictor of 
      oxaliplatin-induced PPN.
FAU - Tanishima, Hiroyuki
AU  - Tanishima H
AD  - Department of Surgery, National Hospital Organization, Osaka Minami Medical 
      Center, 2-1 Kidohigashimachi, Kawachinagano, Osaka, 586-8521, Japan. 
      drspock@ommc-hp.jp.
FAU - Tominaga, Toshiji
AU  - Tominaga T
AD  - Department of Surgery, National Hospital Organization, Osaka Minami Medical 
      Center, 2-1 Kidohigashimachi, Kawachinagano, Osaka, 586-8521, Japan.
FAU - Kimura, Masamichi
AU  - Kimura M
AD  - Department of Surgery, National Hospital Organization, Osaka Minami Medical 
      Center, 2-1 Kidohigashimachi, Kawachinagano, Osaka, 586-8521, Japan.
FAU - Maeda, Tsunehiro
AU  - Maeda T
AD  - Department of Surgery, National Hospital Organization, Osaka Minami Medical 
      Center, 2-1 Kidohigashimachi, Kawachinagano, Osaka, 586-8521, Japan.
FAU - Shirai, Yasutsugu
AU  - Shirai Y
AD  - Department of Surgery, National Hospital Organization, Osaka Minami Medical 
      Center, 2-1 Kidohigashimachi, Kawachinagano, Osaka, 586-8521, Japan.
FAU - Horiuchi, Tetsuya
AU  - Horiuchi T
AD  - Department of Surgery, National Hospital Organization, Osaka Minami Medical 
      Center, 2-1 Kidohigashimachi, Kawachinagano, Osaka, 586-8521, Japan.
LA  - eng
PT  - Journal Article
DEP - 20161205
PL  - Germany
TA  - Support Care Cancer
JT  - Supportive care in cancer : official journal of the Multinational Association of 
      Supportive Care in Cancer
JID - 9302957
RN  - 0 (Organoplatinum Compounds)
RN  - 04ZR38536J (Oxaliplatin)
RN  - Q573I9DVLP (Leucovorin)
RN  - U3P01618RT (Fluorouracil)
RN  - Folfox protocol
SB  - IM
MH  - Adult
MH  - Aged
MH  - Antineoplastic Combined Chemotherapy Protocols/administration & dosage/*adverse 
      effects/therapeutic use
MH  - Chemotherapy, Adjuvant
MH  - Chronic Disease
MH  - Colorectal Neoplasms/drug therapy
MH  - Female
MH  - Fluorouracil/administration & dosage/adverse effects
MH  - Humans
MH  - Leucovorin/administration & dosage/adverse effects
MH  - Male
MH  - Middle Aged
MH  - Multivariate Analysis
MH  - Organoplatinum Compounds/administration & dosage/*adverse effects
MH  - Oxaliplatin
MH  - Peripheral Nervous System Diseases/*chemically induced
MH  - Predictive Value of Tests
MH  - Retrospective Studies
MH  - Risk Factors
OTO - NOTNLM
OT  - Acute neuropathy
OT  - Oxaliplatin
OT  - Peripheral neuropathy
OT  - Predictor of persistent peripheral neuropathy
EDAT- 2016/12/07 06:00
MHDA- 2017/10/13 06:00
CRDT- 2016/12/07 06:00
PHST- 2016/08/29 00:00 [received]
PHST- 2016/11/25 00:00 [accepted]
PHST- 2016/12/07 06:00 [pubmed]
PHST- 2017/10/13 06:00 [medline]
PHST- 2016/12/07 06:00 [entrez]
AID - 10.1007/s00520-016-3514-6 [pii]
AID - 10.1007/s00520-016-3514-6 [doi]
PST - ppublish
SO  - Support Care Cancer. 2017 May;25(5):1383-1389. doi: 10.1007/s00520-016-3514-6. 
      Epub 2016 Dec 5.